Highest-materiality recent filing
Armata Pharma receives $2.5M additional DoD funding for AP-SA02 Phase 3 readiness
Received $2.5M additional non-dilutive funding from U.S. DoD; total DoD award now $28.7M for AP-SA02 development.
Armata posts Q1 net loss of $115.3M ($3.16/diluted share); secures $25M Innoviva loan
Net loss of $115.3M vs $6.5M in Q1 2025; loss includes non-cash items from warrant amendments.
Armata receives FDA Fast Track for AP-SA02 phage therapy for S. aureus bacteremia
Fast Track designation enables rolling BLA review and potential Accelerated Approval and Priority Review.
Armata Pharma Q4 net loss $124.3M on $105.8M non-cash fair value loss; going concern noted
Q4 2025 grant revenue $1.1M vs $1.2M YoY; R&D expenses $6.1M vs $8.5M YoY.
Armata delays Q4/FY2025 earnings; FDA grants QIDP for phage candidate AP-SA02
Will delay Q4/FY2025 financial results announcement; expects to file 10-K by March 31, 2026 due date.
FDA grants QIDP designation to Armata's AP-SA02 for S. aureus bacteremia
AP-SA02 receives QIDP for intravenous adjunct treatment of complicated MSSA/MRSA bacteremia.
Armata extends credit maturity to June 2027 and warrants to Jan 2031 with Innoviva affiliate
Maturity of four credit agreements with Innoviva Sub extended to June 1, 2027.
Armata Pharma receives FDA EOP2 support for AP-SA02 Phase 3 in S. aureus bacteremia
FDA confirmed Phase 2a diSArm data support advancement of AP-SA02 to a Phase 3 superiority study.
Armata enters ATM offering agreement for up to $100M of common stock
Entered Capital on Demand Sales Agreement with JonesTrading for at-the-market offering of common stock up to $100M.
Armata Q3 loss from ops $7.8M; AP-SA02 Phase 2a shows efficacy, cGMP facility commissioned
Q3 2025 grant revenue $1.2M (vs $3.0M prior year); R&D expense $5.8M (vs $9.5M).
Armata AP-SA02 phage cocktail hits primary endpoint in Phase 2a S. aureus bacteremia trial
Day 12 clinical response 88% AP-SA02 vs 58% placebo (p=0.047) by blinded investigators; 83% vs 58% by adjudication committee.
Q2 2025 operating loss of $6.8M vs. $11.9M loss in Q2 2024; cash at $4.3M as of June 30, 2025.
Armata's AP-SA02 shows 100% clinical response in Phase 1b/2a S. aureus bacteremia trial
Primary endpoints met: safety, tolerability, and clinical response in ITT (n=50).
Armata Q1 net loss $6.5M, cash $11.7M; AP-SA02 Phase 1b/2a topline due H1 2025
Net loss of $6.5M ($0.18 basic EPS) vs $25.0M loss in Q1 2024; includes $5.2M non-cash gain on convertible loan.
Armata receives $4.65M additional DoD funding for phage therapy trial; topline data Q2 2025
Received $4.65M additional non-dilutive DoD funding for AP-SA02; total award now $26.2M.
Armata Q4 net income $2.6M; Phase 2 AP-PA02 positive; $10M credit deal
Q4 net income $2.6M ($0.07 basic, -$0.23 diluted) vs net loss $19.8M YoY; includes $14.2M non-cash gain.
Armata Pharma enters $10M secured credit agreement with Innoviva at 14% p.a., matures March 2026
$10 million term loan from Innoviva at 14.0% annual interest, secured by substantially all assets.
Armata Pharmaceuticals Announces Phase 2 Tailwind Study Results for Inhaled AP-PA02 in NCFB Subjects
Post-hoc analysis showed statistically significant reduction of P.a. CFUs at day 17 (P=0.05) and day 24 (P=0.015).
Amended credit agreements with Innoviva; maturity moved to January 10, 2026.
Armata Pharma Q3 net loss $5.5M; Phase 2 Tail wind enrolled, topline data expected by year-end
Net loss $5.5M ($0.15/share) vs $31.2M loss in Q3 2023; includes $6.9M non-cash gain on convertible debt.
Full enrollment (n=50) achieved for intravenous AP-SA02 in Phase 1b/2a diSArm study targeting Staphylococcus aureus bacteremia.
Armata Q2 operating loss $11.9M; AP-PA02 Phase 2 enrollment complete, topline H2 2024
Q2 2024 operating loss $11.9M vs $9.6M in Q2 2023; R&D $8.5M, G&A $3.4M.
Armata Pharma Q1 operating loss $10.2M; secures $35M loan at 14% from Innoviva
Grant revenue $1.0M (up from $0.8M YoY); R&D expense $8.0M (down from $9.6M); G&A $3.2M (up from $2.5M).
Armata Pharma Q4 loss $9.6M; secures $35M loan at 14%, matures June 2025
Q4 2023 loss from operations $(9.6)M vs $(10.3)M in Q4 2022; cash $13.5M at Dec 31, 2023.
Armata secures $35M secured term loan from Innoviva at 14% interest, maturity June 2025
$35M loan from Innoviva Strategic Opportunities (Innoviva wholly-owned subsidiary, Armata's largest shareholder).
Armata appoints Dr. Deborah Birx as CEO, secures $25M credit from Innoviva
Dr. Deborah L. Birx appointed CEO and Board member; former Innoviva Board member and world-renowned healthcare leader.
Armata Pharmaceuticals CEO Dr. Brian Varnum departs; severance includes 12-month salary continuation
Dr. Brian Varnum's employment terminated July 10, 2023; separation agreement signed July 14, 2023.
Armata Pharma secures $25M loan from Innoviva, appoints Dr. Deborah Birx as CEO
Enters $25M secured term loan with Innoviva Strategic Opportunities LLC at 14% interest, matures Jan 2025.
Armata Q1 loss widens to $11.3M; positive Ph1b/2a data for AP-PA02; closes $30M convertible
Positive topline data from AP-PA02 Ph1b/2a in cystic fibrosis; first patient dosed in Phase 2 NCFB study.
Armata reports Q4 2022 loss of $10.3M; positive phage trial data, $30M financing closed
R&D expenses $9.6M in Q4 2022, up from $4.8M in Q4 2021, driven by clinical trial investment.
On November 13, 2024 (the “Termination Date”), the Company terminated the employment of Mina Pastagia, M.D. (“Dr. Pastagia”), Chief Medical Officer of the Company, effective as of the close of business on the Termination Date.
On September 26, 2024, Armata Pharmaceuticals, Inc. (the “ Company ”) disclosed that it had reached an agreement with Richard Rychlik, the Company’s Vice President, Corporate Controller, pursuant to which Mr. Rychlik’s employment would conclude effective as of September 30, 2024.
reached an agreement with Richard Rychlik, the Company’s Vice President, Corporate Controller, pursuant to which Mr. Rychlik’s employment will conclude effective as of September 30, 2024.
On July 31, 2024, Armata Pharmaceuticals, Inc. (the “ Company ”) entered into an employment letter agreement (the “ Agreement ”) with David House, pursuant to which he has agreed to serve as the Company’s Senior Vice President, Finance, effective August 16, 2024 (the “ Effective Date ”).
On September 15, 2023, Richard Rychlik, Corporate Controller of Armata Pharmaceuticals, Inc. (“Armata” or the “Company”), was promoted to serve as Armata’s principal financial officer
Julianne Averill of Danforth Advisors, LLC, who resigned as Chief Financial Officer on the same day.
On July 14, 2023, Armata Pharmaceuticals, Inc. (the “Company”) and Dr. Brian Varnum, the Company’s former Chief Executive Officer, entered into a separation and release agreement
On July 11, 2023, the Company announced that the Board of Directors (the “Board”) had appointed Dr. Deborah Birx, 67, to the position of Chief Executive Officer and as a member of the Board
On July 10, 2023, the Company terminated Dr. Brian Varnum as its Chief Executive Officer
On May 4, 2023, the Company’s Board of Directors (the “ Board ”) appointed Julianne Averill to serve, effective as of May 2, 2023, as Chief Financial Officer of the Company and in such capacity, also serve as principal financial officer and principal accounting officer of the Company.
On May 1, 2023 (the “ Termination Date ”), in connection with the planned closure of the Company’s San Diego, CA office, Armata Pharmaceuticals, Inc. (the “ Company ”) terminated the employment of Erin Butler, Vice President, Finance and Administration (and principal financial officer and principal accounting officer) of the Company, effective as of close of business on the Termination Date.
On March 25, 2022, Steve R. Martin notified Armata Pharmaceuticals, Inc. (the “Company”) that he intends to retire as Chief Financial Officer and Senior Vice President (and Principal Financial and Accounting Officer) of the Company effective as of June 30, 2022 (the “Transition Date”).
Max materiality 0.85 · Median 0.60 · Most common event other_material